Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD81 | P60033 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637858 | 1.00 | CD81 (0.38) | CD81PPARGBACE1PTGS1AKR1C3 | |
| SCHEMBL45793 | 0.93 | — | — | |
| SCHEMBL28832685 | 0.93 | CD81 (0.41) | CD81PPARGBACE1PTGS1AKR1C3 | |
| SCHEMBL16092 | 0.93 | — | — | |
| Ethylene Glycol SCHEMBL28863335 | 0.91 | CD81 (0.40) | CD81PPARGBACE1PTGS1AKR1C3 | |
| SCHEMBL28531941 | 0.91 | CD81 (0.40) | CD81PPARGBACE1PTGS1AKR1C3 | |
| Acetone SCHEMBL8337338 | 0.91 | CD81 (0.40) | CD81PPARGBACE1PTGS1AKR1C3 | |
| Phosphine SCHEMBL28166002 | 0.91 | CD81 (0.40) | CD81PPARGBACE1PTGS1AKR1C3 | |
| Benzene SCHEMBL28203817 | 0.88 | AKR1C3 (0.40) | CD81PPARGBACE1PTGS1AKR1C3 | |
| SCHEMBL11503429 | 0.87 | CD81 (0.36) | CD81PPARGBACE1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732525-B2 | Polymers for paper and paperboard coatings | CIBA SPECIALTY CHEMICALS WATER TREATMENTS LIMITED (GB) | 2010-06-08 | — | — | US | claimed |
| EP-2171047-A1 | REMOVAL OF BY-PRODUCTS FROM CROSSLINKABLE PREPARATIONS | Henkel AG & Co. KGaA (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009013093-A1 | REMOVAL OF BY-PRODUCTS FROM CROSSLINKABLE PREPARATIONS | HENKEL AG & CO. KGAA (DE) | 2009-01-29 | — | — | WO | claimed |
| WO-2023004044-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES BY INHIBITING FSH | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220211768-A1 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | ALLERGAN SALES, LLC | 2022-07-07 | — | — | US | disclosed |
| US-20220204921-A1 | CONDITIONED MEDIUM AND EXTRACELLULAR MATRIX COMPOSITIONS FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS | HISTOGEN INC (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220031760-A1 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | ALLERGAN SALES, LLC | 2022-02-03 | — | — | US | disclosed |
| US-11191780-B2 | Extracellular matrix compositions for the treatment of cancer or immunological diseases | ADAPTIVE BIOLOGIX, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210299036-A1 | CONDITIONED MEDIUM AND EXTRACELLULAR MATRIX COMPOSITIONS AND USES THEREOF | ALLERGAN SALES, LLC | 2021-09-30 | — | — | US | disclosed |
| US-20210254008-A1 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | ALLERGAN SALES, LLC | 2021-08-19 | — | — | US | disclosed |
| WO-2021163429-A1 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | ALLERGAN SALES, LLC (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20040110687-A1 | Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy | SANGSTAT MEDICAL CORPORATION | 2004-06-10 | — | — | US | disclosed |
| WO-2004045554-A2 | CYTOMODULATING PEPTIDES FOR TREATING INTERSTITIAL CYSTITIS | SANGSTAT MEDICAL CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004037196-A2 | CYTOMODULATING PEPTIDES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | SANGSTAT MEDICAL CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003072061-A2 | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL TOXICITY INDUCED BY CYTOABLATIVE THERAPY | SANGSTAT MEDICAL CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003061602-A2 | COMBINATION THERAPY FOR TREATMENT OF HIV INFECTION | SANGSTAT MEDICAL CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1237547-A2 | COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION | ISIS INNOVATION LIMITED (GB) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001003680-A2 | COMPOUNDS FOR INHIBITING DISEASES AND PREPARING CELLS FOR TRANSPLANTATION | ISIS INNOVATION LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| WO-1999053939-A9 | TREATMENT OF OSTEOPOROSIS WITH LEPTIN | MAYO FOUNDATION (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-1999053939-A1 | TREATMENT OF OSTEOPOROSIS WITH LEPTIN | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1999-10-28 | — | — | WO | disclosed |